Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLD Boundless Bio	$1.18 -48.7%	$59.97	$1.00 ▼ $4.72	$26.42M	-1.34	102,520 shs	96,520 shs
HALO Halozyme Therapeutics	$57.15 -0.8%	$55.03	$42.01 ▼ $70.51	$7.04B	1.15	1.76 million shs	1.24 million shs
IOVA Iovance Biotherapeutics	$1.87 -3.1%	$1.98	$1.64 ▼ $12.51	$624.46M	0.85	9.12 million shs	6.77 million shs
MNTA Momenta Pharmaceuticals	$52.48	$52.44	$12.21 ▼ $52.53	$6.25B	1.71	1.94 million shs	N/A
XLRN Acceleron Pharma	$178.75	$176.25	$108.82 ▼ $189.99	$10.93B	0.13	572,759 shs	N/A

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLD Boundless Bio	+0.77%	+11.85%	+11.85%	-3.28%	-71.97%
HALO Halozyme Therapeutics	-0.83%	+5.74%	+6.13%	-5.10%	+7.91%
IOVA Iovance Biotherapeutics	-3.11%	+6.61%	-16.52%	-43.33%	-75.96%
MNTA Momenta Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
XLRN Acceleron Pharma	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BOLD Boundless Bio	2.7837 of 5 stars	3.1	5.0	0.0	0.0	0.6	1.7	1.3
HALO Halozyme Therapeutics	4.8262 of 5 stars	2.1	4.0	0.0	4.4	2.1	2.5	4.4
IOVA Iovance Biotherapeutics	4.7325 of 5 stars	4.3	1.0	0.0	4.2	2.3	4.2	1.3
MNTA Momenta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XLRN Acceleron Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BOLD Boundless Bio	2.25	Hold	$4.00	238.98% Upside
HALO Halozyme Therapeutics	2.17	Hold	$62.50	9.36% Upside
IOVA Iovance Biotherapeutics	2.50	Moderate Buy	$12.22	553.59% Upside
MNTA Momenta Pharmaceuticals	0.00	N/A	N/A	N/A
XLRN Acceleron Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest XLRN, BOLD, HALO, IOVA, and MNTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	HALO Halozyme Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$55.00
6/2/2025	BOLD Boundless Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
5/29/2025	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00
5/28/2025	BOLD Boundless Bio	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$15.00 ➝ $3.00
5/27/2025	BOLD Boundless Bio	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$17.00 ➝ $2.00
5/14/2025	HALO Halozyme Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$73.00 ➝ $62.00
5/13/2025	HALO Halozyme Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
5/13/2025	HALO Halozyme Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform	$47.00
5/12/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $8.00
5/12/2025	IOVA Iovance Biotherapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $10.00

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BOLD Boundless Bio	N/A	N/A	N/A	N/A	$6.76 per share	N/A
HALO Halozyme Therapeutics	$1.08B	6.49	$4.61 per share	12.39	$2.86 per share	19.98
IOVA Iovance Biotherapeutics	$212.68M	2.94	N/A	N/A	$2.33 per share	0.80
MNTA Momenta Pharmaceuticals	$23.87M	261.69	N/A	N/A	$4.59 per share	11.43
XLRN Acceleron Pharma	$92.52M	118.15	N/A	N/A	$11.74 per share	15.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BOLD Boundless Bio	-$65.36M	N/A	N/A	N/A	N/A	N/A	-41.60%	-34.53%	N/A
HALO Halozyme Therapeutics	$444.09M	$3.76	15.20	9.19	0.38	44.76%	136.91%	26.05%	8/5/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$372.18M	-$1.24	N/A	N/A	N/A	-176.49%	-49.71%	-39.18%	8/6/2025 (Estimated)
MNTA Momenta Pharmaceuticals	-$290.05M	-$3.03	N/A	N/A	N/A	-757.61%	-61.44%	-45.28%	N/A
XLRN Acceleron Pharma	-$166.03M	-$4.21	N/A	N/A	N/A	-226.01%	-32.11%	-29.45%	N/A

Latest XLRN, BOLD, HALO, IOVA, and MNTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	HALO Halozyme Therapeutics	$1.22	N/A	N/A	N/A	$282.66 million	N/A
5/9/2025	Q1 2025	BOLD Boundless Bio	-$0.68	-$0.71	-$0.03	-$0.71	N/A	N/A
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million
5/6/2025	Q1 2025	HALO Halozyme Therapeutics	$0.98	$1.11	+$0.13	$0.93	$231.21 million	$264.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BOLD Boundless Bio	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MNTA Momenta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XLRN Acceleron Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BOLD Boundless Bio	0.35	22.15	22.15
HALO Halozyme Therapeutics	3.13	8.39	7.30
IOVA Iovance Biotherapeutics	N/A	4.18	3.64
MNTA Momenta Pharmaceuticals	N/A	6.38	6.38
XLRN Acceleron Pharma	N/A	12.14	12.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BOLD Boundless Bio	N/A
HALO Halozyme Therapeutics	97.79%
IOVA Iovance Biotherapeutics	77.03%
MNTA Momenta Pharmaceuticals	N/A
XLRN Acceleron Pharma	90.35%

Insider Ownership

Company	Insider Ownership
BOLD Boundless Bio	21.10%
HALO Halozyme Therapeutics	2.40%
IOVA Iovance Biotherapeutics	10.30%
MNTA Momenta Pharmaceuticals	3.40%
XLRN Acceleron Pharma	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BOLD Boundless Bio	207	22.39 million	17.66 million	No Data
HALO Halozyme Therapeutics	390	123.22 million	120.26 million	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	299.54 million	Optionable
MNTA Momenta Pharmaceuticals	131	119.03 million	N/A	Optionable
XLRN Acceleron Pharma	312	61.16 million	60.12 million	Optionable

XLRN, BOLD, HALO, IOVA, and MNTA Headlines

Recent News About These Companies

Acceleron P Stock Price Today | NASDAQ: XLRN Live - Investing.com

June 28, 2025 | investing.com

UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal

January 2, 2025 | benzinga.com

Acceleron advances cold fusion technology

December 17, 2024 | neimagazine.comN

Acceleron Banks on Muons for Colder Fusion

December 6, 2024 | msn.com

Merck preps filings after blockbuster-in-waiting Winrevair succeeds in severe PAH study

November 26, 2024 | fiercepharma.comF

Acceleron attracts turbocharged demand for debut Swissie

October 17, 2024 | globalcapital.comG

Acceleron Fusion has raised $15M to take a stab at colder fusion, filing reveals

October 5, 2024 | techcrunch.comT

Acceleron Fusion has raised $15M to take another stab at cold fusion, filing reveals

October 1, 2024 | yahoo.com

Merck confirms $11.5bn Acceleron takeover deal

August 6, 2024 | pharmaphorum.comP

Earnings to Watch Next Week: ON Semiconductor, Ferrari, General Motors and Moderna in Focus

April 26, 2024 | fxempire.comF

Big Pharma Q1 earnings roundup: AstraZeneca, BMS, Merck, Sanofi

April 26, 2024 | mmm-online.comM

ORBIMED CAPITAL GP II LLC's Net Worth

February 27, 2024 | benzinga.com

XLRN Historical Data

October 20, 2023 | investing.com

MSD eyes March FDA decision on PAH drug sotatercept

October 15, 2023 | pharmaphorum.comP

Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley

April 15, 2023 | thestreet.com

Astellas Pharma Inc

March 17, 2023 | reuters.com

HempStreet partners with MGC Pharma launches ArtemiC

January 30, 2023 | health.economictimes.indiatimes.com

Acceleron Corp Becomes a Digital Correspondent Bank

December 14, 2022 | finance.yahoo.com

Pharma Contract Sales Market Report 2022-2032

November 30, 2022 | finance.yahoo.com

Merck to buy Imago for $1.35 bln to broaden portfolio of blood disorder drugs

November 21, 2022 | reuters.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock
By Chris Markoch | July 2, 2025
View Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
By Chris Markoch | June 29, 2025
View 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
Why Meta Stock Investors Should Watch Its Bold Bet on Scale AI
By Leo Miller | June 19, 2025
View Why Meta Stock Investors Should Watch Its Bold Bet on Scale AI
Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside
By Gabriel Osorio-Mazilli | June 26, 2025
View Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside

XLRN, BOLD, HALO, IOVA, and MNTA Company Descriptions

Boundless Bio NASDAQ:BOLD

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.

Halozyme Therapeutics NASDAQ:HALO

$57.15 -0.48 (-0.83%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$57.16 +0.01 (+0.02%)

As of 07/11/2025 06:23 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Iovance Biotherapeutics NASDAQ:IOVA

$1.87 -0.06 (-3.11%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$1.88 +0.01 (+0.48%)

As of 07/11/2025 07:56 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Momenta Pharmaceuticals NASDAQ:MNTA

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

Acceleron Pharma NASDAQ:XLRN

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time